Orexo

Orexo
About Us
Contacts
Quotes
Change country

Follow us:
Share:
Subscribe:

About Us

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2021 amounted to SEK 565 million and the number of employees was 121. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed. For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.

Contacts

Orexo
Box 303 751 05 Uppsala
+46 (0)18 780 88 00
+46 (0)18 780 88 88
http://www.orexo.com
info@orexo.se

Quotes

With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.

Nikolaj Sørensen, President and CEO

Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.

Nikolaj Sørensen, CEO, about Digital Therapies

I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.

Nikolaj Sørensen, President and CEO

Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®

Nikolaj Sørensen, President and CEO

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Interim report January-March 2014

Fri, Apr 25, 2014 08:00 CET

Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2013.Zubsolv®, now with broader market access First quarter 2014 · Total net revenues amounted to MSEK 101.9 (139.8). Revenues from launched products, excluding one-off milestone, amounted to MSEK 101.9 (72.1). · Earnings after tax were MSEK -21.1 (27.5). · Earnings per share were SEK -0.66 (0.95). · Cash flow from operating activities amounted to MSEK -99.7 (-5.0). · Cash and cash equivalents amounted to MSEK30.7 (218.9) before non-utilized

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Contacts

Quotes

Interim report January-March 2014

Subscribe

Media